News

When a new medicine gets approved for use and for sale in a specific region, it’s usually given a brand name by the pharmaceutical company who discovered or developed it.

‘Unapproved medicines’, ‘compassionate use’, ‘early access drugs’..

Vacancy: 'Full Stack' Social Media Manager - TheSocialMedwork is a fast-growing, multicultural and mission-driven social impact startup with real potential.

A personalised vaccine which boosts a patient’s own immune system has nearly doubled the number of women surviving ovarian cancer by two years.

Following an earlier negative decision, NICE is now recommending NHS use of Roche’s immunotherapy Tecentriq for lung cancer.

Rubraca (rucaparib), already approved as a treatment for BRCA positive ovarian cancer, has been approved as a maintenance therapy for ovarian cancer regardless of BRCA mutation. 

The FDA approves Blincyto (blinatumomab) for patients with B-cell ALL, who are in remission but still have minimal residual disease.

FDA approves Tasigna (nilotinib) for certain pediatric patients with Ph+ CML in chronic phase.

FDA approves Genentech’s Lucentis (ranibizumab injection) syringe for diabetic macular edema and diabetic retinopathy.

FDA expands approval of Adcetris (brentuximab vedotin) for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.